Introductory Chapter: Bile Duct Cancer by Rodrigo, Luis & Suarez, Adolfo
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
Introductory Chapter: Bile Duct 
Cancer
Luis Rodrigo and Adolfo Suarez
1. Epidemiology and associated diseases
Cholangiocarcinoma (CC) is the most characteristic malignant tumour affect-
ing to the bile ducts. It is a rare neoplasm that originates in the cells of the biliary 
epithelium. In the USA, it has a mean incidence of 1 case/100,000 inhabitants/year.
They are classified into three groups, with respect to their location within the 
biliary tree: (1) intrahepatic, (2) the upper and middle thirds and (3) the distal part 
of the common bile duct.
Intrahepatic tumours are the least frequent. They behave like primary hepatic 
tumours. Perihilar, or Klatskin, tumours are the most frequent, accounting for 
60–80% of the total.
Their incidence increases with age, more cases appearing in patients aged 
between 50 and 70 years, with a clear predominance in men.
The diseases most frequently associated with it are primary sclerosing chol-
angitis (PSC), choledochal cysts, chronic infections with the parasite Clonorchis 
sinensis (typical of Asian countries and with a predominant intrahepatic location) 
and the presence of cholelithiasis and choledocholithiasis. The presence of PSC is 
an important risk factor, given that it occurs in 30% of cases. In many patients, no 
known risk factors are found.
2. Clinical presentation
Presentation depends fundamentally on the location of the tumour, although 
more than 90% of cases exhibit obstructive jaundice as their main sign. Other 
associated symptoms are episodes of cholangitis (which occur frequently after 
manipulation of the biliary tract), weight loss, abdominal pain, rebel pruritus and 
altered liver function test values, with elevated serum levels of bilirubin, alkaline 
phosphatase (AP) and gamma-glutamyl transpeptidase (GGT).
Transaminases can be quite elevated. The levels of serum tumour markers type 
CEA and CA 19-9 are usually raised, although they are of little diagnostic use due to 
their lack of sensitivity and specificity for this purpose. There are currently no other 
markers available that are useful for diagnosing or following up these tumours.
3. Diagnostic procedures
Abdominal ultrasound (AU) produces results of varying quality, depend-
ing on the location of the tumour. Distal tumours can be confused with primary 
pancreatic or periampullary neoplasms. Hilar tumours are usually infiltrative, 
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characteristically causing dilation of the intrahepatic bile duct and collapse of the 
extrahepatic duct.
Computerised axial tomography (CAT) can help identify the type and stage of 
an existing tumour.
Magnetic resonance cholangiography (MRC) is the current imaging technique of 
choice for studying the bile duct, providing information simultaneously about the 
bile duct and its locoregional extension.
Endoscopic ultrasound (EU) is especially useful in tumours located in the distal 
third of the duct, enabling the tumour to be sampled and its cytology determined.
Endoscopic retrograde cholangiopancreatography (ERCP) and percutane-
ous cholangiography (PC) are currently reserved for the palliative treatment of 
obstructive jaundice, through the placement of biliary prostheses.
4. Classification
The classification of bile duct tumours is controversial and complex. Perihilar 
tumours are customarily divided into four types, depending on their extension and 
type of surgical resection, following the Bismuth-Corlette classification [1–3].
The working group of the Memorial Sloan-Kettering Cancer Center in New York 
has proposed a new classification that is better correlated with the prognosis, 
but which is very complex and does not take into account the current concepts of 
resectability.
In general, it is considered appropriate to separate perihilar tumours and those 
of the distal bile duct into separate groups.
5. Treatment
Resectability is determined by the absence of metastases, including retropan-
creatic nodes, non-invasion of the great vessels and the possibility of performing 
a surgical resection with free margins. Some groups recommend to do an explor-
atory laparoscopy prior to the indication of surgery, to rule out the presence of 
dissemination.
The discovery of lymph node involvement below the hepatoduodenal ligament 
indicates inoperability.
The placement of a biliary prosthesis before surgery is controversial. While some 
groups consider that it ameliorates the jaundice, allows the collection of biopsies 
and facilitates access to the bile duct after surgery, others postulate that it makes 
complications, especially cholangitis, more likely to arise [4–6].
The type of resection depends on the location of the tumour. In distal tumours, 
a cephalic duodenopancreatectomy is performed. This should be carried out in a 
reference centre to reduce the likelihood of perioperative morbidity (30%).
In hilar lesions, the resection should be individualised with respect to the 
extent of the tumour. A liver resection should normally be carried out that includes 
segments IV and V, extended according to the size of the tumour mass in order to 
ensure disease-free resection margins.
Liver transplantation is not a feasible therapeutic option because of the high rate 
of recurrence that occurs during follow-up.
In cases in which resection is not possible, it is advisable to drain the bile duct 
through catheters that are carefully placed through endoscopy or inserted percu-
taneously. Endoscopic drainage is considered easier and safer in distal tumours, 
while the percutaneous approach is more effective in proximal tumours. The most 
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common short-term complication is cholangitis, although this can be prevented 
by giving antibiotics before placement. In the long term, the obstruction of the 
prosthesis, either by tumour progression, biliary detritus or food debris, prevents 
the flow of bile through the duct, and the jaundice reappears.
There is currently not enough scientific evidence available to make firm recom-
mendations about the use of adjuvant therapy after surgery. The Guidelines of the 
European Society of Medical Oncology (ESMO) suggest the use of chemotherapy 
and/or palliative radiotherapy after non-curative resections and of chemoradio-
therapy after curative resections.
Neoadjuvant therapy is not usually recommended because of the deterioration 
that patients usually present at the time of diagnosis [7–10].
6. Prognosis and prevention
The prognosis of bile duct cancer is bad. Malignant tumours of the bile duct 
are usually diagnosed at advanced stages, with infiltration of neighbouring organs 
such as the liver, gallbladder, adjoining vessels and distant metastases, which often 
contraindicates surgery. Average survival is 12–24 months. Distal tumours have a 
better prognosis, with a 5-year survival of 15–25%.
Screening programmes have not proved to be effective for the early detection 
of these tumours. However, in carriers of PSC, it is advisable to undertake periodic 
surveillance using imaging techniques (e.g. MRC) and the determination of CA 
19-9 serum levels, although none of these procedures is sufficiently specific [11, 12].
Author details
Luis Rodrigo* and Adolfo Suarez
Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain
*Address all correspondence to: lrodrigosaez@gmail.com
4Bile Duct Cancer
[1] Paul A, Kaiser GM, Molmenti EP, 
Scroeder T, Vernadakis S, Oezcelik A,  
et al. Klatskin tumors and the 
accuracy of the Bismuth-Corlette 
classification. The American Surgeon. 
2011;77:1695-1699
[2] Li B, Xiong XZ, Zhou Y, Wu 
SJ, You Z, Lu J, et al. Prognostic 
value of lymphovascular invasion 
in Bismuth-Corlette type IV hilar 
cholangiocarcinoma. World Journal of 
Gastroenterology. 2017;23:6685-6693
[3] Ji GW, Zhu FP, Wang K, Jiao CY, 
Shao ZC, Li XC. Clinical implications 
of biliary confluence pattern for 
Bismuth-Corlette type IV hilar 
cholangiocarcinoma applied to hemi-
hepatectomy. Journal of Gastrointestinal 
Surgery. 2017;21:666-675
[4] Coelen RJS, Roos E, Wiggers JK, 
Besselink MG, Buis CL, Busch ORC, 
et al. Endoscopic versus percutaneous 
biliary drainage in patients with 
resectable perihilar cholangiocarcinoma: 
A multicenter randomised controlled 
trial. The Lancet Gastroenterology & 
Hepatology. 2018;3:681-690
[5] Tang Z, Yang Y, Meng W, Li X. Best 
option for preoperative drainage 
in Klatskin tumor: A systematic 
review and meta-analysis. Medicine 
(Baltimore). 2017;96:e8372
[6] Hameed A, Pang T, Chiou J, Pleass H, 
Lam V, Hollands M, et al. Percutaneous 
vs. endoscopic pre-operative biliary 
drainage in hilar cholangiocarcinoma. 
A systematic review and meta-analysis. 
HPB: The Official Journal of the 
International Hepato Pancreato Biliary 
Association. 2016;18:400-410
[7] Esnaola NF, Meyer JE, Karachristos 
A, Maranki JL, Camp ER, Denlinger 
CS. Evaluation and management 
of intrahepatic and extrahepatic 
cholangiocarcinoma. Cancer. 
2016;122:1349-1369
[8] Nakano M, Ariizumi SI, Yamamoto 
M. Intrahepatic cholangiocarcinoma. 
Seminars in Diagnostic Pathology. 
2017;34:160-166
[9] Waseem D, Tushar P. Intrahepatic, 
perihilar and distal cholangiocarcinoma: 
Management and outcomes. Annals of 
Hepatology. 2017;16:133-139
[10] Chun YS, Javie M. Systemic and 
adjuvant therapies for intrahepatic 
cholangiocarcinoma. Cancer Control. 
2017;24:1073274817729241
[11] Kim HJ, Kim JS, Joo MK, Lee BJ, 
Yeon JE, Park JJ, et al. Hepatolithiasis 
and intrahepatic cholangiocarcinoma: 
A review. World Journal of 
Gastroenterology. 2015;21:13418-13431
[12] Buisson Y. Control of 
Opisthorchis viverrini infection for 
cholangiocarcinoma prevention. 
Bulletin de la Société de Pathologie 
Exotique. 2017;110:61-67
References
